Announced Tue, 21 Jul · 07:13 IST
Lupin spins out oncology programs to Kaveri for 82.2 percent stake
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.3%1-day move
₹2486.70
prior close
₹2484.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-0.2-0.1+0.1-3.3-3.6-4.5-3.1——————
Up moveDown movePending
AI summary
Lupin Inc USA, wholly owned subsidiary, has licensed two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), to newly formed Kaveri Therapeutics. In exchange, Lupin Inc received 82.2 percent equity stake (332,000 shares) valued at USD 1.6 million. Kaveri, incorporated May 2026, will advance the programs through global clinical trials. Lupin provides seed funding; Kaveri will raise more capital. Both programs showed positive data at ASCO.
Likely market impact
Strategic spin-out to focused oncology entity. Lupin retains majority control and upside from future clinical milestones.